BioPharm International-01-01-2020

Achieving effective manufacturing processes and sufficient capacity remains a top priority across a diversified biologic drug pipeline.

The promise of new therapies is tempered by the need for affordability, safety, and ethics.

While cell and gene therapies differ in many ways, some of the best practices for process development and validation are similar.

With a positive employment market, some biopharma professionals explore options for career advancement.

Pressures on FDA will affect industry’s success in bringing new therapies to market.

Temperature-sensitive biologics are lyophilized to preserve therapeutic viability, but the process presents complexities and challenges that are as yet not fully understood.

Industry experts debate the pros and cons of “going bigger” than the 2000-L industry norm in a single vessel.

This study aims to use plant-leaf extract for the green synthesis of gold nanoparticles and to evaluate their antibacterial and antioxidant activity.

Focusing on symptoms instead of root causes locks teams into a corrective, rather than preventive, mindset.

Click the title above to open the BioPharm International January 2020 issue in an interactive PDF format.